BioSpace News Archive

Business

GTX Corp Third Quarter 2017 Summary Results

Product revenues increased by 7% over 2016 comparable period.

November 20, 2017

·

8 min read

Biotech Bay

“Hair for the Holidays” Social Media Campaign Drives Increased Patient Awareness and New Patient Inquiries for the ARTAS Robotic Hair Restoration System

The campaign, which is running from September to December, includes targeted, direct-to-patient advertising for robotic hair restoration with the ARTAS System on Facebook and Twitter.

November 20, 2017

·

1 min read

AxoGen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day

Additionally, the company will announce its newest application in breast reconstruction neurotization and outline its continued effort to evaluate expansions of the company’s portfolio of products in the surgical management of pain.

November 20, 2017

·

8 min read

Genetown

Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)

Flexion has hired and trained more than 100 field sales representatives, known as Musculoskeletal Business Managers, who are now deployed across the country.

November 20, 2017

·

6 min read

Drug Development

Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes

Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, Inc. (Janssen) on a worldwide basis.

November 20, 2017

·

5 min read

Business

Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017

Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ENT and allergy specialists.

November 20, 2017

·

1 min read

Beleave Announces $5M Non-Brokered Private Placement of Units

The Company may, as a result, increase the size of the Non-Brokered Offering by up to 20%, for aggregate gross proceeds of approximately $6 million.

November 20, 2017

·

3 min read

Drug Development

Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial

With the achievement of this milestone, Summit continues to expect to report results from this initial 24-week dosing period in the first quarter of 2018.

November 20, 2017

·

6 min read

Policy

TESARO Announces European Commission Approval of ZEJULA for Women With Recurrent Ovarian Cancer

ZEJULA was approved by the FDA on March 27, 2017 and is marketed by TESARO in the United States.

November 20, 2017

·

13 min read

Business

ProQR Announces Results for the Third Quarter of 2017

Runway into the second half of 2019: cash of €39.7 million at end of Q3.

November 20, 2017

·

22 min read